WO2007089334A3 - Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein - Google Patents

Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein Download PDF

Info

Publication number
WO2007089334A3
WO2007089334A3 PCT/US2006/047515 US2006047515W WO2007089334A3 WO 2007089334 A3 WO2007089334 A3 WO 2007089334A3 US 2006047515 W US2006047515 W US 2006047515W WO 2007089334 A3 WO2007089334 A3 WO 2007089334A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkinson
enzymatically active
assay
parkin
preparations useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/047515
Other languages
French (fr)
Other versions
WO2007089334A2 (en
Inventor
Jennifer A Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Priority to CA002632657A priority Critical patent/CA2632657A1/en
Priority to EP06848996A priority patent/EP1969367B1/en
Priority to US12/096,890 priority patent/US20090317825A1/en
Priority to AT06848996T priority patent/ATE520025T1/en
Priority to JP2008545762A priority patent/JP2009519040A/en
Publication of WO2007089334A2 publication Critical patent/WO2007089334A2/en
Publication of WO2007089334A3 publication Critical patent/WO2007089334A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function. The invention also provides recombinant, enzymatically active, Parkin protein produced in prokaryotic expression systems, such as E. coli cells. Methods for purification of Parkin protein are also provided.
PCT/US2006/047515 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein Ceased WO2007089334A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002632657A CA2632657A1 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
EP06848996A EP1969367B1 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics
US12/096,890 US20090317825A1 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
AT06848996T ATE520025T1 (en) 2005-12-12 2006-12-12 TEST FOR PARKINSON'S DISEASE THERAPEUTICS
JP2008545762A JP2009519040A (en) 2005-12-12 2006-12-12 Assays for the treatment of Parkinson's disease and enzymatically active Parkin preparations useful therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74996405P 2005-12-12 2005-12-12
US60/749,964 2005-12-12

Publications (2)

Publication Number Publication Date
WO2007089334A2 WO2007089334A2 (en) 2007-08-09
WO2007089334A3 true WO2007089334A3 (en) 2008-01-10

Family

ID=38179819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047515 Ceased WO2007089334A2 (en) 2005-12-12 2006-12-12 Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Country Status (6)

Country Link
US (2) US20070212679A1 (en)
EP (1) EP1969367B1 (en)
JP (1) JP2009519040A (en)
AT (1) ATE520025T1 (en)
CA (1) CA2632657A1 (en)
WO (1) WO2007089334A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017348B1 (en) 2005-12-12 2011-09-13 Elan Pharma International Limited Assay for Parkinson's Disease therapeutics
US10508117B2 (en) 2014-09-16 2019-12-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
EP2243033B1 (en) * 2008-01-31 2012-06-06 Elan Pharma International Limited Thermal denaturation screening assay to identify candidate compounds for prevention and treatment of parkinson's disease
US20100021941A1 (en) * 2008-07-25 2010-01-28 Progenra, Incorporated Methods of identifying modulators of ubiquitin ligases
ES2418459B1 (en) * 2008-10-09 2014-08-12 Universitat Autònoma De Barcelona RELATING PROTEIN AGGREGATION WITH SURVEY OF LEAVING
BR112012009329A2 (en) 2009-10-22 2016-06-07 Gilead Sciences Inc purine or deazapurine derivatives useful for the treatment of viral infections (inter alia)
SI3166607T1 (en) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
JP6814991B2 (en) * 2016-02-01 2021-01-20 学校法人順天堂 Screening method for parkin activator
CN113924114A (en) 2019-05-22 2022-01-11 吉利德科学公司 Combination of a TLR7 modulatory compound and an HIV vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079459A2 (en) * 2001-03-29 2002-10-10 Nsgene A/S Means for inhibiting proteolytical processing of parkin
EP1416272A1 (en) * 2001-06-28 2004-05-06 Riken Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease
US20040214763A1 (en) * 2002-07-18 2004-10-28 Aventis Pharma, S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
US20050042607A1 (en) * 2000-02-24 2005-02-24 Yoshikuni Mizuno Parkin protein as ubiquitin ligase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (en) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 A therapeutic agent for diseases involving brain neurotransmitters consisting of pterin derivatives
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
CA2632657A1 (en) * 2005-12-12 2007-08-09 Elan Pharmaceuticals, Inc. Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042607A1 (en) * 2000-02-24 2005-02-24 Yoshikuni Mizuno Parkin protein as ubiquitin ligase
WO2002079459A2 (en) * 2001-03-29 2002-10-10 Nsgene A/S Means for inhibiting proteolytical processing of parkin
EP1416272A1 (en) * 2001-06-28 2004-05-06 Riken Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease
US20040214763A1 (en) * 2002-07-18 2004-10-28 Aventis Pharma, S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANDOPADHYAY ET AL: "Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENCE, OXFORD, GB, vol. 20, no. 2, November 2005 (2005-11-01), pages 401 - 411, XP005118674, ISSN: 0969-9961 *
MATSUDA NORIYUKI ET AL: "Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 6, 8 December 2005 (2005-12-08), pages 3204 - 3209, XP002453916, ISSN: 0021-9258 *
TANAKA KEIJI ET AL: "Parkin is linked to the ubiquitin pathway", JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 79, no. 9, September 2001 (2001-09-01), pages 482 - 494, XP002440053, ISSN: 0946-2716 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017348B1 (en) 2005-12-12 2011-09-13 Elan Pharma International Limited Assay for Parkinson's Disease therapeutics
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors
US10508117B2 (en) 2014-09-16 2019-12-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator

Also Published As

Publication number Publication date
JP2009519040A (en) 2009-05-14
CA2632657A1 (en) 2007-08-09
ATE520025T1 (en) 2011-08-15
US20070212679A1 (en) 2007-09-13
US20090317825A1 (en) 2009-12-24
EP1969367A2 (en) 2008-09-17
WO2007089334A2 (en) 2007-08-09
EP1969367B1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
ATE405650T1 (en) PRODUCTION OF WHOLE ANTIBODIES IN PROKARYONTIC CELLS
NO2017027I1 (en) efmoroctocog alfa or a bio-equivalent drug in accordance with Article 10 (4) of Directive 2001/83 / EC, as protected by the basic patent.
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
WO2004089396A3 (en) Anti-fungal peptidomimetics
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
MXPA02012743A (en) Il-17 molecules and uses thereof.
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2003022028A3 (en) Methods, reagents, kits and apparatus for protein function analysis
BRPI0513477A (en) Angiotensin-like protein 4 compositions and processes
WO2005016227A3 (en) Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
AU2001292843A1 (en) Crystal structure of bace and uses thereof
WO2004054607A3 (en) Stable therapeutic proteins
DE60114018D1 (en) CELLS PRESENTED PEPTIDES
ATE520025T1 (en) TEST FOR PARKINSON'S DISEASE THERAPEUTICS
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2007134118A3 (en) Protein based composition and methods of using same
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
PL1962815T3 (en) Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
MX2007011381A (en) Spirulin composition rich in active principles, method for obtaining same and use thereof.
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
PL374550A1 (en) Il-17 like molecules and uses thereof
Akpinar et al. Peptidase activity assays using protein substrates
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2632657

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008545762

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006848996

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12096890

Country of ref document: US